Drug Profile
BIA 20
Alternative Names: BIA-20Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator BIAL
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Diabetes-mellitus in Portugal
- 28 Nov 2021 No recent reports of development identified for preclinical development in Obesity in Portugal
- 30 Oct 2017 Preclinical trials in Diabetes mellitus in Portugal before October 2017 (BIAL pipeline, October 2017)